Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema
Tóm tắt
To report the effect of simultaneous intravitreal dexamethasone (DEX) and aflibercept for the treatment of diabetic macular edema (DME). This retrospective analysis of an open-label, multicenter, consecutive case series included 102 eyes of 81 patients with DME. Patients were selected into two groups. The control group consisted of 50 eyes treated with aflibercept alone, and the combination group consisted of 52 eyes treated with simultaneous DEX implant and aflibercept injection. The primary endpoints were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 6. The secondary endpoint was the interval of retreatment. Baseline BCVA increased and CRT decreased at 6 months in both groups. Pseudophakic eyes in the combination group exhibited significantly greater BCVA improvement compared with phakic eyes (p = 0.031). Fewer intravitreal treatments were required for eyes treated with combination therapy than for those treated with aflibercept alone (1.56 ± 0.54 vs. 4.04 ± 1.26, p < .0001), with a mean retreatment interval of 3.66 ± 0.69 months. Simultaneous intravitreal DEX and aflibercept achieved non-inferior improvement of visual and anatomic outcomes compared with aflibercept alone for DME, but exhibited a significantly longer treatment interval and superior visual outcome in pseudophakic eyes. This therapeutic approach is considered a valid strategy for treating DME in the era of COVID-19.
Tài liệu tham khảo
Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843
Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564. https://doi.org/10.2337/dc11-1909
Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801. https://doi.org/10.1016/j.ophtha.2011.12.039
Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11):2247–2254. https://doi.org/10.1016/j.ophtha.2014.05.006
Wells JA, Glassman AR, Ayala AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203. https://doi.org/10.1056/NEJMoa1414264
Denys P, Miere A, Colantuono D, Jung C, Souied EH (2021) Intravitreal injections during COVID-19 outbreak: protective measures, total duration of care and perceived quality of care in a tertiary retina center. Eur J Ophthalmol. https://doi.org/10.1177/11206721211003488
Bajka A, Wiest MRJ, Hamann T, Toro MD, Zweifel SA (2021) Assessment of patients’ confidence regarding a new triage concept in a medical retina clinic during the first COVID-19 outbreak. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph18115846
Iovino C, Peiretti E, Giannaccare G, Scorcia V, Carnevali A (2021) Evolving treatment paradigm in the management of diabetic macular edema in the Era of COVID-19. Front Pharmacol 12:670468. https://doi.org/10.3389/fphar.2021.670468
Gonzalez VH, Campbell J, Holekamp NM et al (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol i data. Am J Ophthalmol 172:72–79. https://doi.org/10.1016/j.ajo.2016.09.012
Bressler NM, Beaulieu WT, Maguire MG et al (2018) Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol t. Am J Ophthalmol 195:93–100. https://doi.org/10.1016/j.ajo.2018.07.030
Furino C, Boscia F, Reibaldi M, Alessio G (2021) Intravitreal therapy for diabetic macular edema: an update. J Ophthalmol 2021:6654168. https://doi.org/10.1155/2021/6654168
Al-Khersan H, Hariprasad SM, Salehi-Had H (2019) Dexamethasone and Anti-VEGF combination therapy for the treatment of diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 50(1):4–7. https://doi.org/10.3928/23258160-20181212-01
Amoaku WM, Saker S, Stewart EA (2015) A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond) 29(9):1115–1130. https://doi.org/10.1038/eye.2015.110
Boyer DS, Yoon YH, Belfort R Jr et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024
Gillies MC, Lim LL, Campain A et al (2014) A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 121(12):2473–2481. https://doi.org/10.1016/j.ophtha.2014.07.002
Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 4(4):011599. https://doi.org/10.1002/14651858.CD011599.pub2
Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: early treatment diabetic retinopathy study report number 2. Ophthalmology 94:761–74. https://doi.org/10.1016/s0161-6420(87)33527-4
Klaassen I, Van Noorden CJ, Schlingemann RO (2013) Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 34:19–48. https://doi.org/10.1016/j.preteyeres.2013.02.001
Schram MT, Chaturvedi N, Schalkwijk C et al (2003) Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 26(7):2165–2173. https://doi.org/10.2337/diacare.26.7.2165
Johnson MW (2009) Etiology and treatment of macular edema. Am J Ophthalmol 147(1):11-21.e11. https://doi.org/10.1016/j.ajo.2008.07.024
Maturi RK, Glassman AR, Liu D et al (2018) Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a drcr network phase 2 randomized clinical trial. JAMA ophthalmology 136(1):29–38. https://doi.org/10.1001/jamaophthalmol.2017.4914
Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW (2015) A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina (Philadelphia, Pa) 35(8):1604–1614. https://doi.org/10.1097/iae.0000000000000533
Güler E, Totan Y, Betül Güragaç F (2017) Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema. Cutan Ocul Toxicol 36(2):180–184. https://doi.org/10.3109/15569527.2015.1127254
Lim JW, Lee HK, Shin MC (2012) Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde 227(2):100–106. https://doi.org/10.1159/000331935
Neto HO, Regatieri CV, Nobrega MJ et al (2017) Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 48(9):734–740. https://doi.org/10.3928/23258160-20170829-08
Ahmadieh H, Ramezani A, Shoeibi N, et al. (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 246(4) 483–489. Doi: https://doi.org/10.1007/s00417-007-0688-0
Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA (2012) Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina (Philadelphia, Pa) 32(2):314–321. https://doi.org/10.1097/IAE.0b013e31822f55de
Yaseri M, Zeraati H, Mohammad K et al (2014) Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. J Ophthalmic Vis Res 9(4):453–460. https://doi.org/10.4103/2008-322x.150818
Mehta H, Fraser-Bell S, Nguyen V, Lim LL, Gillies MC (2018) Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. Br J Ophthalmol 102(4):479–482. https://doi.org/10.1136/bjophthalmol-2017-310737
Maturi RK, Pollack A, Uy HS et al (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study. Retina (Philadelphia, Pa) 36(6):1143–1152. https://doi.org/10.1097/iae.0000000000001004
Pacella F, Romano MR, Turchetti P et al (2016) An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol 9(10):1427–1432. https://doi.org/10.18240/ijo.2016.10.10
Al-Latayfeh M, Abdel Rahman M, Shatnawi R (2021) Outcome of single dexamethasone implant injection in the treatment of persistent diabetic macular edema after anti-VEGF treatment: real-life data from a tertiary hospital in jordan. Clin Ophthalmol (Auckland, NZ) 15:1285–1291. https://doi.org/10.2147/opth.S303670
Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–806
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F et al (2017) Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmol J Int d’ophtalmol Int J Ophthalmol Zeitschrift fur Augenheilkunde 237(4):185–222. https://doi.org/10.1159/000458539
Sheu SJ, Cheng CK, Kuo HK et al (2018) Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review. Clin Ophthalmol (Auckland, NZ) 12:2189–2198. https://doi.org/10.2147/opth.S170089
Distefano LN, Garcia-Arumi J, Martinez-Castillo V, Boixadera A (2017) Combination of anti-VEGF and laser photocoagulation for diabetic macular edema: a review. J Ophthalmol 2017:2407037. https://doi.org/10.1155/2017/2407037
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113(9):1533–1538. https://doi.org/10.1016/j.ophtha.2006.02.065
Elman MJ, Qin H, Aiello LP et al (2012) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119(11):2312–2318. https://doi.org/10.1016/j.ophtha.2012.08.022